✦ LIBER ✦

Adjuvant and down-staging treatment with imatinib in gastrointestinal stromal tumors

✍ Scribed by B. Nilsson; A. Andersson; H. Ahlman

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 51 KB
Volume: 98
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.21043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant imatinib therapy for gastrointe

Adjuvant imatinib therapy for gastrointestinal stromal tumors

✍ Peter W.T. Pisters; Chiara Colombo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

Imatinib as adjuvant therapy for gastroi

Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review

✍ Munira Essat; Katy Cooper 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 266 KB 👁 1 views

## Abstract The high risk of recurrence in resected gastrointestinal stromal tumor (GIST) highlights the need for effective adjuvant treatment. This review evaluates the clinical efficacy and safety of imatinib for adjuvant treatment of localized KIT (CD117)‐positive resected GIST. Relevant studies

Adjuvant and neoadjuvant imatinib therap

Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors

✍ Burton L. Eisenberg; Jonathan C. Trent 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 212 KB

## Abstract Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has off

Surgical intervention following imatinib

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)

✍ Sun Jin Sym; Min-Hee Ryu; Jae-Lyun Lee; Heung Moon Chang; Tae-Won Kim; Hee Cheol 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

Novel V600E BRAF mutations in imatinib-n

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

✍ Narasimhan P. Agaram; Grace C. Wong; Tianhua Guo; Robert G. Maki; Samuel Singer; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 462 KB

## Abstract __BRAF__ and __NRAS__ are commonly mutated in cancer and represent the most frequent genetic events in malignant melanoma. More recently, a subset of melanomas was shown to overexpress KIT and harbor __KIT__ mutations. Although most gastrointestinal stromal tumors (GISTs) exhibit activa

Protein expression of cancer testis anti

Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors

✍ Daniel Perez; Fabian Hauswirth; Dirk Jäger; Urs Metzger; Eleftherios Pierre Sama 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 304 KB

## Abstract Cancer testis antigens (CTAs) have been identified in various tumors as immunological tumor targets. In gastrointestinal stromal tumor (GIST), the prediction of malignant potential remains difficult but is crucial in the era of adjuvant imatinib treatment. Here, we analyzed the impact o